Entero Healthcar Q2 FY26 Earnings Analysis

- Targeting 30% revenue growth in FY'26, combining both organic and inorganic growth. - Organic growth remains strong at around 15%, with inorganic contributing approximately 16%, summing to a like-for-like growth of 31%. - Acquisitions expected to contribute about Rs. 500 crores in revenue this year, supporting inorganic growth. - Rate of acquisitions likely to taper off in the next 2-3 years as market penetration and product expansion mature. - Expansion into higher-margin categories like medical devices, diagnostics, and specialty pharma to drive richer product mix and incremental growth. - Deepening wallet share with existing customers by expanding product range and geographic presence. - Growth expected to be more robust from organic channels as acquisition reliance decreases. - Operational excellence and technology integration to improve efficiency, supporting sustainable volume and sales growth.

- Entero Healthcare Solutions targets **30% revenue growth in FY'26**, combining organic and inorganic growth. - EBITDA margin guidance is **4%+ for the full year FY'26**, with current Q1 margin at 3.6% expected to improve as revenue growth accelerates. - Operating leverage benefits will drive margin expansion as fixed costs are stable; salary hikes are already accounted for in Q1. - Gross margins improved by 83 bps YoY to 9.9%, with further procurement efficiencies and richer product mix expected. - Profit after tax increased 47% YoY to Rs. 30 crores in Q1, supported by a tax-efficient structure maintaining a low effective tax rate of ~17%-18%. - Positive operating cash flows anticipated for full FY'26 with ongoing working capital optimization targeting 60 days by year-end. - Inorganic growth contribution (~15%-16%) will taper over next 2-3 years; organic growth is expected to sustain long-term profitability and EPS growth.

- Entero Healthcare has already made significant investments in proprietary technology, including building its own customizable ERP systems integrated with platforms like Facebook and WhatsApp, and customer-facing apps. - They are also developing a health tech platform to integrate directly with retailer systems. - Most technology infrastructure investments are already in place, so no significant additional capex is expected in technology going forward. - Future focus will be on better utilization and capitalization of existing technology to drive efficiencies such as working capital reduction. - The company is actively pursuing acquisitions (M&A) to expand geographic presence and product offerings, with 4 acquisitions in the pipeline and more deals being evaluated. - Operating cash flows are a key driver for funding acquisitions going forward; currently, IPO funds are being used for acquisitions. - The company targets to reduce working capital days by 10% by the end of the financial year as part of operational improvements.

- The company is currently using IPO funds to finance acquisitions, indicating no immediate need for new equity fundraising. - They aim to be cash flow positive on operating cash flow, which will enable future acquisitions to be funded internally. - There is no explicit mention of any new fundraising through debt in the current quarter. - The company is working on tax-efficient funding structures for subsidiaries, which suggests optimization of existing funds rather than new fundraising. - Management indicated that as inorganic growth needs diminish over the next 2-3 years, cash flow generation will improve, reducing the need for external funding. - No announcement or indication of planned new equity or debt fundraising in the near future was made during the call.

- The transcript does not explicitly mention the current or expected order book or pending orders in numeric terms. - However, regarding acquisitions (which can be linked to future orderbook/revenue), the company targets about Rs. 500 crores of recognized acquisition revenue for the year. - Four acquisition deals are in the pipeline; two already closed with revenue starting to flow from Q2, and two pending closure dependent on external factors like drug licenses. - Additional deals beyond these four are under evaluation, with announcements expected within the next month. - Overall, Entero Healthcare is on track for 30% revenue growth in FY'26, including both organic and inorganic growth, reflecting strong ongoing business momentum. - No specific order backlog figures are disclosed in the call.